Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYZPJU)

Drug Name

L-733560 Drug Info

Synonyms

AC1L4318; L 733560; Pneumocandin B0, 1-((4R,5R)-5-(2-aminoethoxy)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-((3R)-3-hydroxy-L-ornithine)

Indication

Disease Entry	ICD 11	Status	REF
Aspergillosis	1F20	Terminated	[1]

Cross-matching ID

PubChem CID: 177900
CAS Number: CAS 150283-06-0
TTD Drug ID: DMYZPJU

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Fungal 1,3-beta-glucan synthase (Fung GSC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caspofungin	DMGQIPT	Candidiasis	1F23	Approved	[3]
Micafungin	DM6Y3AN	Aspergillosis	1F20	Approved	[4]
Rezafungin	DMQ4CSX	Candidiasis	1F23	Approved	[5]
Ibrexafungerp	DMK1IPV	Vulvovaginal Candidiasis	1F23.10	Approved	[6]
Anidulafungin	DM8QM5U	Aspergillosis	1F20	Approved	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fungal 1,3-beta-glucan synthase (Fung GSC2)	TT0SFXH	FKS2_YEAST	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003552)
2	Discovery of Novel Antifungal (1,3)--d-Glucan Synthase Inhibitors
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74.
5	Antifungal drugs: What brings the future?. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343.
6	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72.
7	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.